As promised, here are details from a preliminary study showing impressive response rates when Darzalex (daratumumab) is combined with Revlimid and dexamethasone.
Happy Myeloma Monday! I’m not sure how or why the tradition began, but for the seven years I’ve been coming to ASH, Monday has always been the biggest myeloma news day.
I’m here at the American Society of Hematology (ASH) meetings in Orlando, helping CrowdCare Foundation founder, Jenny Ahlstrom. The big news here today focused on an impressive breakthrough in T cell therapy.
I’m almost packed. Tomorrow I’ll be driving three hours south to Orlando to attend my 7th American Society of Hematology (ASH) annual meeting. Seven years! How the multiple myeloma therapy landscape has changed. Heck, things have been turned upside down in three short weeks.
In my haste to get the news out about elotuzumab’s FDA approval yesterday, I mistakenly relied on a Cure Magazine article that stated Kyprolis was the drug used in combination with elo. I was surprised, but ran with it. I should have known better. The Cure Magazine article was mistaken. Elotuzumab (Empliciti), Revlimid and dexamethasone […]
Bring it on! The FDA has approved elotuzumab (Empliciti) for use in relapsed multiple myeloma patients; the third new drug approval in three weeks!
I had an opportunity to interview several Takeda Pharmaceutical team members about the company’s new oral, proteasome inhibitor, Ninlaro (ixazomib), yesterday afternoon.
By most accounts, ixazomib (trade name, Ninlaro) should work as well or even better than Velcade. Preliminary reports are hopeful that adverse side effects may be fewer and more tolerable, too. “But storm clouds on the horizon?”
The FDA approved Takeda’s oral proteasome inhibitor, ixazomib, late this morning. First daratumumab on on Monday and now ixazomib today.
According to officials at the FDA, yesterday “the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments.”
I expected daratumumab to garner FDA approval sometime after ASH. So when I saw a news alert earlier today announcing that Darzalex had been approved, I didn’t pay any attention. But it didn’t take long for me to figure out that Darzalex is the new trade name for daratumumab. By any name, this is wonderful […]
We’ve been following the progress of allogeneic (donor) stem cell transplant survivor, David, from Tampa, for a year. The young myeloma patient handled the difficult procedure better than most, but he openly expressed disappointment that his transplant didn’t completely snuff out his cancer.
If a tree falls in the forest–and no one hears it–did it fall at all? If I’m on the cover of Healthmonitor Magazine promoting multiple myeloma awareness–and I can’t find the article or cover shot online–did anyone read it?
More good news about Mike Barron and his successful run with daratumumab. Mike wants all to know that his latest cycle picks up where the last on left off: daratumumab and dex is doing the trick. “It’s like a miracle,” Mike wrote me.
I ran across this comprehensive article about the emergence of new myeloma immunotherapies on OncLive.com over the weekend. It features a who’s who of myeloma experts.
I met with Dr. Tricot this morning for my pre-transplant check. As expected, I’m good to go. I wasn’t expecting such encouraging, eye-opening test results.
I’m often said our readers are my best resource. Early reports about the new immunotherapy, daratumumab, have been good. Mike, from North Carolina, recently enrolled in a dara trial. He emailed me about how great it’s working for him and agreed to share an email he sent his friends, trumpeting the early results. Here’s a […]
I saw my radiation oncologist today. Dr. Perkins is confident he can mop up any active lesions the second transplant doesn’t get.
I had a chance to see myeloma patient and CrowdCare Foundation co-founder, Jenny Ahlstrom, in Boston last week. She made an impassioned plea to anyone that would listen to help her raise money to pay for two cutting edge T cell clinical trials; one in the U.S. and one in Germany.
We were all so excited! Dying myeloma patient, Stacy from Minnesota, responded miraculously to Mayo Clinic’s experimental measles vaccine therapy. Yet apparently attempts to match this early success is fleeting.